OncoMatch/Clinical Trials/NCT06550141
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Is NCT06550141 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Emapalumab and Cyclophosphamide for large b-cell lymphoma.
Treatment: Emapalumab · Cyclophosphamide · Fludarabine Phosphate · Axicabtagene Ciloleucel — This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL). The research study involves the following study interventions: * Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy) * Axicabtagene Ciloleucel * Emapalumab
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemoimmunotherapy — first-line
large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy
Must have received: systemic therapy
relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy
Cannot have received: autologous stem cell transplant
Exception: allowed if >6 weeks before planned axicabtagene ciloleucel infusion
Autologous stem cell transplant within 6 weeks of planned axicabtagene ciloleucel infusion
Cannot have received: allogeneic stem cell transplantation
History of allogeneic stem cell transplantation
Lab requirements
Blood counts
anc ≥1000/ul; platelet count ≥50,000/ul; absolute lymphocyte count ≥100/ul
Kidney function
creatinine clearance (as estimated by cockcroft gault or ckd-epi) ≥ 30 ml/min
Liver function
serum alt/ast ≤2.5 per institutional uln; total bilirubin ≤1.5 mg/dl, except in subjects with gilbert's syndrome
Cardiac function
cardiac ejection fraction ≥ 40%, no clinically significant pericardial effusion, and no clinically significant ecg findings
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify